Beam Therapeutics Inc. — Q2 2020 Form 10-Q Summary
Business context and reporting period
Beam Therapeutics is a research-stage biotechnology company developing precision genetic medicines based on proprietary base-editing technology. All programs remained in research or preclinical development; the company had not initiated clinical development or generated product-sale revenue. This report covers the three and six months ended June 30, 2020, with comparative periods ended June 30, 2019.
Financial performance and liquidity
| Metric | Three months ended June 30, 2020 | Three months ended June 30, 2019 | Six months ended June 30, 2020 | Six months ended June 30, 2019 |
|---|---|---|---|---|
| License revenue | $6 thousand | $6 thousand | $12 thousand | $6 thousand |
| Research and development expense | $19.4 million | $12.7 million | $40.9 million | $21.9 million |
| General and administrative expense | $6.9 million | $5.0 million | $13.7 million | $8.9 million |
| Loss from operations | $(26.3) million | $(17.7) million | $(54.6) million | $(30.8) million |
| Net loss | $(34.2) million | $(17.9) million | $(64.7) million | $(31.5) million |
| Net loss per share | $(0.69) | $(3.38) | $(1.65) | $(6.26) |
| Net cash used in operating activities | Not separately provided for the quarter | $(50.2) million | $(37.2) million |
Revenue was immaterial relative to operating expenses, so operating and net margins were substantially negative and not meaningful as performance measures. The six-month net loss increased by $33.2 million, primarily reflecting higher research and development spending and increased fair-value expense on success payment liabilities.
- At June 30, 2020, cash and cash equivalents were $125.3 million, marketable securities were $102.6 million, and total cash, cash equivalents and marketable securities were $228.0 million.
- Total assets were $300.0 million and stockholders’ equity was $230.8 million, compared with a stockholders’ deficit of $201.1 million at December 31, 2019.
- Total liabilities were $69.2 million, including $19.2 million of derivative liabilities, $29.6 million of operating lease liabilities and $6.6 million of equipment financing obligations.
- Cash, cash equivalents and restricted cash increased by $88.1 million during the first six months of 2020, primarily because of $192.5 million of net IPO proceeds, partly offset by operating and investing cash uses.
- The company stated that its cash, cash equivalents and marketable securities as of June 30, 2020 were expected to fund operations for at least the next 12 months, but additional financing will be required to support longer-term operations and growth.
Material changes versus the prior comparable period
- R&D expense increased 53% to $19.4 million in the second quarter and 87% to $40.9 million for the first six months. Increases were attributed to laboratory supplies and outsourced services, personnel, facilities, depreciation, stock compensation and license or milestone costs.
- R&D headcount increased from 69 employees at June 30, 2019 to 127 at June 30, 2020; general and administrative headcount increased from 18 to 24.
- G&A expense increased 39% in the quarter and 54% for the six-month period, including higher public-company insurance, personnel, stock compensation, administrative and intellectual-property costs.
- The fair value of Harvard and Broad Institute success payment liabilities increased from an aggregate $7.8 million at December 31, 2019 to $19.2 million at June 30, 2020, producing an $11.4 million six-month non-cash expense versus $2.0 million in the prior-year period.
- In February 2020, Beam completed its initial public offering of 12,176,471 shares at $17.00 per share, generating approximately $188.3 million of net proceeds. All outstanding redeemable convertible preferred stock converted into 29,127,523 common shares.
- Marketable securities increased to $102.6 million from $54.6 million at year-end 2019, while property and equipment increased to $25.7 million from $24.3 million.
Guidance, outlook, commentary and unusual items
- Management expected continued significant operating losses and negative operating cash flow for the foreseeable future, with R&D expenses expected to increase as preclinical programs advance and clinical development is initiated.
- Beam remained on track to file its first IND in 2021 and expected to initiate IND-enabling studies for at least one lead program in 2020, subject to COVID-19 not materially delaying timelines.
- Q2 scientific updates included preclinical data for BEAM-102 in sickle cell disease and base-editing proof of concept for alpha-1 antitrypsin deficiency. The company also reported progress across electroporation, lipid nanoparticle and AAV delivery modalities.
- COVID-19 restrictions reduced facility access and required remote work and staggered laboratory shifts. Management stated that the pandemic had not significantly affected the six-month results, but warned that future disruptions could delay preclinical work, IND-enabling studies, supply and clinical timelines.
- In June 2020, Beam announced a collaboration with Magenta Therapeutics concerning conditioning for sickle cell disease and beta-thalassemia programs. In July 2020, it announced collaborations with Boston Children’s Hospital and the Institute of Molecular and Clinical Ophthalmology Basel.
- In August 2020, after the reporting period, Beam entered into a lease to develop a 100,000-square-foot manufacturing facility in North Carolina. The company expects to invest up to $83 million over five years and anticipates operations by the first quarter of 2023.
- In July 2020, Beam issued 175,000 common shares to Bio Palette in satisfaction of milestone obligations. A $2.0 million cash milestone payment and the share obligation were associated with a Bio Palette patent milestone.
- There were no material legal proceedings reported. Management concluded that disclosure controls and procedures were effective as of June 30, 2020, and reported no material changes in internal control over financial reporting.
Important facts for investors to verify
- Whether the cash runway remains consistent with management’s stated estimate after incorporating ongoing losses, planned preclinical and clinical spending, lease commitments and the proposed manufacturing facility.
- The timing and probability of the first IND filing in 2021 and whether COVID-19 or other factors have altered preclinical or regulatory timelines.
- The valuation and potential future cash obligations associated with the $19.2 million Harvard and Broad success payment liabilities.
- The scope, cost, timing and financing of the North Carolina manufacturing facility, including the potential $83 million investment and expected 2023 operational date.
- Progress from preclinical proof of concept to human clinical testing, including safety, off-target editing, delivery and manufacturing risks.
- Potential intellectual-property disputes and licensing risks involving Harvard, the Broad Institute, Editas and third-party CRISPR patent proceedings.
- Future dilution or restrictions from additional equity or debt financing, given the company’s expected continuing losses and lack of product revenue.